{
    "nctId": "NCT04963608",
    "briefTitle": "RWS of Inetetamab HER2 Positive Advanced Breast Cancer",
    "officialTitle": "Real World Study of Inetetamab HER2 Positive Advanced Breast Cancer",
    "overallStatus": "UNKNOWN",
    "conditions": "HER2-positive Advanced Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 100,
    "primaryOutcomeMeasure": "Progression Free Survival(PFS)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Patients with stage IV breast cancer\n2. Patients with HER2 positive status\n3. Patients that received Inetetamab\n4. Patients that began Inetetamab therapy prior to June 30, 2021.\n\nExclusion Criteria:\n\nPatients treated with an investigational anticancer agent Inetetamab",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}